相关实验视频
Updated: May 5, 2026

08:58
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
15.9K
一个随机临床试验
Elisa Pose1,2,3, César Jiménez4,5, Giacomo Zaccherini6,7
1Liver Unit, Hospital Clínic de Barcelona, Barcelona, Spain.
JAMA
|February 5, 2025
概括
在不补偿性肝硬化患者中,simvastatin和rifaximin联合治疗没有改善结果. 与安慰剂相比,该试验没有发现严重并发症,器官衰竭或死亡率的显著降低.
科学领域:
- 肝病学
- 临床试验
- 药理学
背景情况:
- 肝硬化并发症显著影响患者的治疗结果.
- 目前的治疗方法在预防严重的肝硬化并发症方面缺乏有效性.
- 在肝硬化中,simvastatin和rifaximin单独显示出潜在的益处.
研究的目的:
- 评估simvastatin和rifaximin结合治疗的疗效,以改善无补偿性肝硬化患者的治疗结果.
- 评估这种联合治疗对严重并发症和死亡率的影响.
主要方法:
- 这是一项3期双盲,安慰剂对照试验,涉及14家欧洲医院的237名肝硬化患者.
- 患者接受了标准治疗加上simvastatin (20 mg/ d) 和rifaximin (1200 mg/ d) 或安慰剂12个月.
- 主要终点是急性至慢性肝衰竭的发生率;次要终点包括无移植生存率和复合性肝硬化并发症.
主要成果:
- 在接受simvastatin- rifaximin组 (17. 9%) 和安慰剂组 (14. 2%) 之间,急性至慢性肝衰竭的发生率没有显著差异.
- 移植或死亡率 (18. 8% vs 24. 2%) 和肝硬化并发症的发生率 (42. 7% vs 45. 8%) 在两组之间也相似.
- 尽管治疗组中的3名患者出现了骨髓溶解,但不良反应是相似的.
结论:
- 添加到标准治疗中时,simvastatin和rifaximin的组合不会改善肝硬化不补偿的患者的临床结果.
- 可能需要进一步的研究来探索这种患者群体的替代治疗策略.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
522
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
522
Drugs for Treatment of Diarrhea-Predominant IBS
142
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
142
Drugs for Treatment of Constipation-Predominant IBS
130
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
130
Esophageal Varices-II: Clinical Features and Management
37
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
37
Ultrasound II: Endoscopic Ultrasound and FibroScan
66
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Endoscopic Ultrasound (EUS):
66

